Solid Tumor, Adult Clinical Trials in Indianapolis, Indiana

5 studies are recruiting for solid tumor, adult in Indianapolis, Indiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

   First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana

   Locations

   44 in total

   Run by

   TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

   See if you can join NCT06625775 on ClinicalTrials.gov

2. A Study of VET3-TGI in Patients With Solid Tumors

   VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or whe…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Community Health Network, Indianapolis, Indiana

   Locations

   7 in total

   Run by

   KaliVir Immunotherapeutics

   See if you can join NCT06444815 on ClinicalTrials.gov

3. A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

   The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebuli…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   IU Simon Comprehensive Cancer Center, Indianapolis, Indiana

   Locations

   14 in total

   Run by

   Krystal Biotech, Inc.

   See if you can join NCT06228326 on ClinicalTrials.gov

4. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

   This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Community Health Network, Indianapolis, Indiana

   Locations

   37 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT05216432 on ClinicalTrials.gov

5. A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

   This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Community Health Network, Inc., Indianapolis, Indiana

   Locations

   13 in total

   Run by

   GV20 Therapeutics

   See if you can join NCT05669430 on ClinicalTrials.gov